NASDAQ · IRD
Opus Genetics, Inc.
$3.65-$0.03 (-0.82%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.37% below the high.
Loading market information…
NASDAQ · SPRO · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Spero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Spero Therapeutics, Inc.’s forward annual dividend is $0.06 per share, paid quarterly. The forward yield is 5.41% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Spero Therapeutics, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Spero Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$0.25+54.55% vs estimate |
| $5.87M-46.6% vs estimate |
| Q4 2024 | Mar 27, 2025 | -$0.38-8.57% vs estimate | $9.36M+50.9% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.32-18.52% vs estimate | $13.47M+225.86% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.65-$0.03 (-0.82%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.37% below the high.
$2.29-$0.09 (-3.78%)
Acumen Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.39% below the high.
$2.06+$0.07 (+3.52%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.94% below the high.
$1.94-$0.05 (-2.51%)
Seer, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.49% below the high.
$4.22-$0.03 (-0.71%)
Corbus Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.52% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$0.77-$0.16 (-16.89%)
Inovio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.63% below the high.
$1.95+$0.16 (+8.94%)
Seres Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
